Market Overview

UPDATE: Credit Suisse Initiates Sunesis Pharmaceuticals at Outperform Ahead of Phase II Data

Share:
Related SNSS
Biotech Stocks Falling Broadly, Here's Why And How Much
Market Update: Friday's Mid-Day Market Movers: Amazon Shocks The Markets; Anthem, Cigna, StanCorp, Pandora
Premarket Biotech Digest: Amgen Beats, GlaxoSmithKline Corruption Charges, VTv Therapeutics Flops On Debut (Seeking Alpha)

Credit Suisse initiated coverage on Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) with an Outperform rating and a $7.00 price target.

Credit Suisse commented, "SNSS is a binary risk stock for which upside potential and probability of success are not fully reflected in the current share price. In part, we believe this is because the Phase III read out for vosaroxin is not expected until early 2014. However, we believe that shares could move significantly higher ahead of the event. Investors with binary risk tolerance should consider owning SNSS through the VALOR results. SNSS owns global rights to vosaroxin (owes a midteen royalty), so positive results would put SNSS on a path to commercial profitability or a potential premium acquisition."

Sunesis Pharmaceuticals closed at $4.00 on Monday.

Latest Ratings for SNSS

DateFirmActionFromTo
Jul 2015Cowen & CompanyDowngradesOutperformMarket Perform
Jun 2015Roth CapitalMaintainsBuy
Jan 2015BTIG ResearchInitiates Coverage onBuy

View More Analyst Ratings for SNSS
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (SNSS)

Get Benzinga's Newsletters